ArticleCancer cell2020

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.

Dhivya R Sudhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.